This report offers in-depth analysis of data from the CRO industry broken down by geography, therapeutic area and phases of development. Also included are analyses on the CRO industry’s acute clinical research understaffing issue, the growing sponsor demand for ‘unconventional’ Phase I-IV data collection, as well as Brexit’s potential impact on the volume of trial contracts. Lastly, the report includes articles based on interviewing drug development executives about their CRO needs and aggregated CRO appointment intelligence based on editorial coverage from 3Q16.
BioPharm Insight data shows that PRA Health Sciences (NASDAQ:PRAH) and INC Research (NASDAQ:INCR) shared the first position for the most active CRO in 3Q16, leading eight studies each. Covance (NYSE:CVD) came in third position with seven studies, while Parexel (NASDAQ:PRXL) ranked fourth for activity in 3Q16 with six studies.
Eli Lilly (NYSE:LLY) topped the table as the most active among large- and mega-cap sponsors in 3Q16, sharing the first spot with GlaxoSmithKline (LON:GSK) and Gilead (NASDAQ:GILD). Alkermes (NASDAQ:ALK) and Bellicum Pharmaceuticals (NASDAQ:BLCM) were the most active among mid-cap and small-cap sponsors, respectively.
Read the report for additional insight on the clinical trial activity in 3Q16.